Report cover image

Major Depressive Disorder Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

Publisher Expert Market Research
Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319887

Description

The major depressive disorder market attained a value of USD 6.10 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 5.30% , to reach USD 10.22 Billion by 2034.

Major Depressive Disorder Market Overview

Major depressive disorder (MDD) is characterized by persistently low and depressed mood along with a loss of interest in everyday activities. The incidence rate is rising in the younger population due to alcohol and drug abuse. According to the Mental Health America prevalence data of 2023, 16.39% of youth aged between 12-17 years suffered from at least one major depressive episode (MDE) in the previous year. The state prevalence of MDE in youth was reported to be 12.57% in New Jersey and 21.13% in Oregon.

Major depressive disorder is highly prevalent in women, owing to several factors such as hormonal differences, different psychosocial stressors, and childbirth effects. The average onset of this psychiatric disorder is estimated to be 40 years . The rising prevalence of mental illnesses is projected to boost the major depressive disorder market growth in the forecast period.

The market is witnessing steady growth supported by the surge in drug approvals by the health regulatory agencies. For instance, in October 2023, the United States Food and Drug Administration (FDA) approved gepirone ER, marketed as Exxua, to treat major depressive disorder (MDD). The medication developed by Fabre-Kramer Pharmaceuticals, Inc. (a United States pharmaceutical company) targets the serotonin 1A receptor, a key mood regulator. Exxua is the only drug that selectively stimulates the receptor without any adverse symptoms of weight gain or sexual dysfunction. The availability of such drugs in the market will positively influence the market landscape.

The major depressive disorder market demand is further bolstered by the rising geriatric population at a higher risk of developing mental disorders. The rising mental health campaigns and initiatives by the government to support patients suffering from clinical depression are also anticipated to accelerate the market growth in the forecast period.

Major Depressive Disorder Market Trends

Personalized Medicine

There is a growing demand for personalized or precision medicine in treating MDD, where treatments are customized based on individual genetic makeup, lifestyle, and response to past treatments.

Digital Therapeutics

There has been an emergence of digital therapeutics, including apps to track symptoms, and provide therapeutic activities. These tools are becoming an important part of the treatment regimen for MDD.

Combination Therapies

An increasing focus on combination therapies that use a mix of medications, psychotherapy, and lifestyle changes to treat MDD.

Next-Generation Antidepressants

The development of next-generation antidepressants that target new pathways and mechanisms of action beyond the traditional pathways. This includes drugs targeting the glutamatergic system and other novel approaches to treat MDD more effectively and with fewer side effects.

Major Depressive Disorder Market Segmentation
"Global Major Depressive Disorder Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type
  • Benzodiazepines
  • Antidepressant Drugs
  • SSRIs
  • SNRIs
  • Others
The market for treating major depressive disorder (MDD) can be segmented by product type, including benzodiazepines, antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other medications. This market segment comprises the pharmacological options available for managing MDD.

Market Breakup by Treatment Type
  • Medication
  
  • Antidepressant Drugs

    •   
  • Adjunctive Therapies
    • Psychotherapy
      
  • Cognitive Behavioral Therapy (CBT)

    •   
  • Interpersonal Therapy (IPT)

    •   
  • Other Therapeutic Approaches
    • Brain Stimulation Therapies
      
  • Electroconvulsive Therapy (ECT)

    •   
  • Transcranial Magnetic Stimulation (TMS)

    • The major depressive disorder market report includes segmentation based on treatment types. It includes medication, psychotherapy, and brain stimulation therapies. Under medication, options include antidepressant drugs and adjunctive therapies. Psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other therapeutic approaches. Brain stimulation therapies consist of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). This market segment offers a range of interventions available for managing MDD, aligning with patients’ needs and preferences.

    Market Breakup by Diagnosis Tests
    • Psychological Assessments
    • Blood Tests
    • Imaging Technologies
    • Laboratory Tests
    • Other Diagnostic Tools
    Based on diagnostic tests, the major depressive disorder market share includes psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools. This market segment shows the approaches to diagnosing MDD, which forms an essential part of effective treatment planning.

    Market Breakup by Distribution Channel
    • Pharmacies and Retail Stores
    • Online Pharmacies
    • Hospitals and Clinics
    • Others
    Distribution channels in the market include pharmacies and retail stores, online pharmacies, hospitals and clinics, and other channels. The diverse network of these channels helps in accommodating the diverse clinical needs of patients suffering from major depressive disorder.

    Market Breakup by End User
    • Hospitals and Clinics
    • Mental Health Centres
    • Ambulatory Surgical Centres (ASCs)
    Major end users of the major depressive disorder market are hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs). Mental health centers provide mental health care, such as diagnosis and therapy to MDD patients.

    Market Breakup by Region
    • United States
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Japan
    • China
    Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China. North America dominates the regional market, attributed to the high prevalence rates of major depressive disorder. Rapid technological advancements in the healthcare sector and the rise in the geriatric population base, which is more susceptible to develop the condition. Such factors are expected to further bolster the market growth in the region.

    Major Depressive Disorder Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • Lundbeck
    • AbbVie
    • Relmada Therapeutics
    • Axsome Therapeutics
    • Alkermes
    • Intra-Cellular Therapies
    • Allergan plc
    • Pfizer Inc.
    • Sanofi S.A.
    • Johnson & Johnson
    • Merck & Co.
    • Eli Lilly and Company
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca Plc
    • GSK plc
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

    Key Queries Solved in the Major Depressive Disorder Market Report
    • How has the major depressive disorder market performed so far and how is it anticipated to perform in the coming years?
    • What are the major market trends influencing the market?
    • What are the market's major drivers, opportunities, and restraints?
    • Which regional market is expected to lead the market share in the forecast period?
    • Which country is expected to experience expedited growth during the forecast period?
    • How does the prevalence and incidence of major depressive disorder affect the market landscape?
    • How does the rise in the geriatric population impact the major depressive disorder market size?
    • What treatment type of major depressive disorder will dominate the market share?
    • Which diagnostic method is expected to have a high market value in the coming years?
    • Which product type will experience the highest demand in the market segment?
    • How will the ongoing clinical trials impact the market value during the forecast period?
    • What are the factors driving regional disparities in major depressive disorder treatment and outcomes?
    • What are the current unmet needs and challenges in the market?
    • How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
    More Insights On

    Major Depressive Disorder Epidemiology Forecast
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Major Depressive Disorder Market Overview – 8 Major Markets
    3.1 Major Depressive Disorder Market Historical Value (2018-2024)
    3.2 Major Depressive Disorder Market Forecast Value (2025-2034)
    4 Major Depressive Disorder Overview
    4.1 Guidelines and Stages
    4.2 Pathophysiology
    4.3 Screening and Diagnosis
    4.4 Therapy Pathway
    5 Patient Profile
    5.1 Patient Profile Overview
    5.2 Patient Psychology and Emotional Impact Factors
    5.3 Risk Assessment and Therapy Success Rate
    6 Major Depressive Disorder Epidemiology Analysis- 8 Major Markets
    6.1 8MM Epidemiology Scenario Overview (2018-2034)
    6.2 United States Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.3 EU-4 and United Kingdom Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.3.1 Germany Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.3.2 France Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.3.3 Italy Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.3.4 Spain Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.3.5 United Kingdom Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.4 Japan Major Depressive Disorder Epidemiology Forecast (2018-2034)
    6.5 China Major Depressive Disorder Epidemiology Forecast (2018-2034)
    7 Major Depressive Disorder Market Landscape*- 8 Major Markets
    7.1 Major Depressive Disorder Developers Landscape
    7.1.1 Analysis by Year of Establishment
    7.1.2 Analysis by Company Size
    7.1.3 Analysis by Region
    7.2 Major Depressive Disorder Product Landscape
    7.2.1 Analysis by Product Type
    7.2.2 Analysis by Treatment Type
    8 Major Depressive Disorder Treatment Challenges and Unmet Needs
    8.1 Treatment Pathway Challenges
    8.2 Compliance and Drop-Out Analysis
    8.3 Awareness and Prevention Gaps
    9 Cost of Treatment
    10 Major Depressive Disorder Market Dynamics
    10.1 Market Drivers and Constraints
    10.2 SWOT Analysis
    10.2.1 Strengths
    10.2.2 Weaknesses
    10.2.3 Opportunities
    10.2.4 Threats
    10.3 Porter’s Five Forces Model
    10.3.1 Bargaining Power of Suppliers
    10.3.2 Bargaining Power of Buyers
    10.3.3 Threat of New Entrants
    10.3.4 Threat of Substitutes
    10.3.5 Degree of Rivalry
    10.4 Porter’s Five Forces Model
    10.5 Key Demand Indicators
    10.6 Key Price Indicators
    10.7 Industry Events, Initiatives, and Trends
    10.8 Value Chain Analysis
    11 Major Depressive Disorder Market Segmentation (218-2034) - 8 Major Markets
    11.1 Major Depressive Disorder Market (2018-2034) by Product Type
    11.1.1 Market Overview
    11.1.2 Benzodiazepines
    11.1.3 Antidepressant Drugs
    11.1.4 SSRIs
    11.1.5 SNRIs
    11.1.6 Others
    11.2 Major Depressive Disorder Market (2018-2034) by Treatment Type
    11.2.1 Market Overview
    11.2.2 Medication
    11.2.2.1 Antidepressant Drugs
    11.2.2.2 Adjunctive Therapies
    11.2.3 Psychotherapy
    11.2.3.1 Cognitive Behavioral Therapy (CBT)
    11.2.3.2 Interpersonal Therapy (IPT)
    11.2.3.3 Other Therapeutic Approaches
    11.2.4 Brain Stimulation Therapies
    11.2.4.1 Electroconvulsive Therapy (ECT)
    11.2.4.2 Transcranial Magnetic Stimulation (TMS)
    11.3 Major Depressive Disorder Market (2018-2034) by Diagnosis Tests
    11.3.1 Market Overview
    11.3.2 Psychological Assessments
    11.3.3 Blood Tests
    11.3.4 Imaging Technologies
    11.3.5 Laboratory Tests
    11.3.6 Other Diagnostic Tools
    11.4 Major Depressive Disorder Market (2018-2034) by Distribution Channel
    11.4.1 Market Overview
    11.4.2 Pharmacies and Retail Stores
    11.4.3 Online Pharmacies
    11.4.4 Hospitals and Clinics
    11.4.5 Others
    11.5 Major Depressive Disorder Market (2018-2034) by End User
    11.5.1 Market Overview
    11.5.2 Hospitals and Clinics
    11.5.3 Mental Health Centres
    11.5.4 Ambulatory Surgical Centres (ASCs)
    11.6 Major Depressive Disorder Market (2018-2034) by Region
    11.6.1 Market Overview
    11.6.2 United States
    11.6.3 EU-4 and the United Kingdom
    11.6.3.1 Germany
    11.6.3.2 France
    11.6.3.3 Italy
    11.6.3.4 Spain
    11.6.3.5 United Kingdom
    11.6.4 Japan
    11.6.5 China
    12 United States Major Depressive Disorder Market (218-2034)
    12.1 United States Major Depressive Disorder Market Historical Value (2018-2024)
    12.2 United States Major Depressive Disorder Market Forecast Value (2025-2034)
    12.3 United States Major Depressive Disorder Market (2018-2034) by Product Type
    12.3.1 Market Overview
    12.3.2 Benzodiazepines
    12.3.3 Antidepressant Drugs
    12.3.4 SSRIs
    12.3.5 SNRIs
    12.3.6 Others
    12.4 Major Depressive Disorder Market (2018-2034) by Treatment Type
    12.4.1 Market Overview
    12.4.2 Medication
    12.4.2.1 Antidepressant Drugs
    12.4.2.2 Adjunctive Therapies
    12.4.3 Psychotherapy
    12.4.3.1 Cognitive Behavioral Therapy (CBT)
    12.4.3.2 Interpersonal Therapy (IPT)
    12.4.3.3 Other Therapeutic Approaches
    12.4.4 Brain Stimulation Therapies
    12.4.4.1 Electroconvulsive Therapy (ECT)
    12.4.4.2 Transcranial Magnetic Stimulation (TMS)
    13 EU-4 and United Kingdom Major Depressive Disorder Market (218-2034)
    13.1 EU-4 and United Kingdom Major Depressive Disorder Market Historical Value (2018-2024)
    13.2 EU-4 and United Kingdom Major Depressive Disorder Market Forecast Value (2025-2034)
    13.3 EU-4 and United Kingdom Major Depressive Disorder Market (2018-2034) by Product Type
    13.3.1 Market Overview
    13.3.2 Benzodiazepines
    13.3.3 Antidepressant Drugs
    13.3.4 SSRIs
    13.3.5 SNRIs
    13.3.6 Others
    13.4 EU-4 and United Kingdom Major Depressive Disorder Market (2018-2034) by Treatment Type
    13.4.1 Market Overview
    13.4.2 Medication
    13.4.2.1 Antidepressant Drugs
    13.4.2.2 Adjunctive Therapies
    13.4.3 Psychotherapy
    13.4.3.1 Cognitive Behavioral Therapy (CBT)
    13.4.3.2 Interpersonal Therapy (IPT)
    13.4.3.3 Other Therapeutic Approaches
    13.4.4 Brain Stimulation Therapies
    13.4.4.1 Electroconvulsive Therapy (ECT)
    13.4.4.2 Transcranial Magnetic Stimulation (TMS)
    14 Japan Major Depressive Disorder Market (218-2034)
    14.1 Japan Major Depressive Disorder Market Historical Value (2018-2024)
    14.2 Japan Major Depressive Disorder Market Forecast Value (2025-2034)
    14.3 Japan Major Depressive Disorder Market (2018-2034) by Product Type
    14.3.1 Market Overview
    14.3.2 Benzodiazepines
    14.3.3 Antidepressant Drugs
    14.3.4 SSRIs
    14.3.5 SNRIs
    14.3.6 Others
    14.4 Japan Major Depressive Disorder Market (2018-2034) by Treatment Type
    14.4.1 Market Overview
    14.4.2 Medication
    14.4.2.1 Antidepressant Drugs
    14.4.2.2 Adjunctive Therapies
    14.4.3 Psychotherapy
    14.4.3.1 Cognitive Behavioral Therapy (CBT)
    14.4.3.2 Interpersonal Therapy (IPT)
    14.4.3.3 Other Therapeutic Approaches
    14.4.4 Brain Stimulation Therapies
    14.4.4.1 Electroconvulsive Therapy (ECT)
    14.4.4.2 Transcranial Magnetic Stimulation (TMS)
    15 China Major Depressive Disorder Market (218-2034)
    15.1 China Major Depressive Disorder Market Historical Value (2018-2024)
    15.2 China Major Depressive Disorder Market Forecast Value (2025-2034)
    15.3 China Major Depressive Disorder Market (2018-2034) by Product Type
    15.3.1 Market Overview
    15.3.2 Benzodiazepines
    15.3.3 Antidepressant Drugs
    15.3.4 SSRIs
    15.3.5 SNRIs
    15.3.6 Others
    15.4 China Major Depressive Disorder Market (2018-2034) by Treatment Type
    15.4.1 Market Overview
    15.4.2 Medication
    15.4.2.1 Antidepressant Drugs
    15.4.2.2 Adjunctive Therapies
    15.4.3 Psychotherapy
    15.4.3.1 Cognitive Behavioral Therapy (CBT)
    15.4.3.2 Interpersonal Therapy (IPT)
    15.4.3.3 Other Therapeutic Approaches
    15.4.4 Brain Stimulation Therapies
    15.4.4.1 Electroconvulsive Therapy (ECT)
    15.4.4.2 Transcranial Magnetic Stimulation (TMS)
    16 Regulatory Framework
    16.1 Regulatory Overview
    16.1.1 US FDA
    16.1.2 EU EMA
    16.1.3 JAPAN PMDA
    16.1.4 Others
    17 Patent Analysis
    17.1 Analysis by Type of Patent
    17.2 Analysis by Publication Year
    17.3 Analysis by Issuing Authority
    17.4 Analysis by Patent Age
    17.5 Analysis by CPC Analysis
    17.6 Analysis by Patent Valuation
    17.7 Analysis by Key Players
    18 Grants Analysis
    18.1 Analysis by Year
    18.2 Analysis by Amount Awarded
    18.3 Analysis by Issuing Authority
    18.4 Analysis by Grant Application
    18.5 Analysis by Funding Institute
    18.6 Analysis by NIH Departments
    18.7 Analysis by Recipient Organization
    19 Clinical Trials Analysis
    19.1 Analysis by Trial Registration Year
    19.2 Analysis by Trial Status
    19.3 Analysis by Trial Phase
    19.4 Analysis by Therapeutic Area
    19.5 Analysis by Geography
    20 Funding Analysis
    20.1 Analysis by Funding Instances
    20.2 Analysis by Type of Funding
    20.3 Analysis by Funding Amount
    20.4 Analysis by Leading Players
    20.5 Analysis by Leading Investors
    20.6 Analysis by Geography
    21 Partnership and Collaborations Analysis
    21.1 Analysis by Partnership Instances
    21.2 Analysis by Type of Partnership
    21.3 Analysis by Leading Players
    21.4 Analysis by Geography
    22 Supplier Landscape
    22.1 Lundbeck
    22.1.1 Financial Analysis
    22.1.2 Product Portfolio
    22.1.3 Demographic Reach and Achievements
    22.1.4 Mergers and Acquisition
    22.1.5 Certifications
    22.2 AbbVie
    22.2.1 Financial Analysis
    22.2.2 Product Portfolio
    22.2.3 Demographic Reach and Achievements
    22.2.4 Mergers and Acquisition
    22.2.5 Certifications
    22.3 Relmada Therapeutics
    22.3.1 Financial Analysis
    22.3.2 Product Portfolio
    22.3.3 Demographic Reach and Achievements
    22.3.4 Mergers and Acquisition
    22.3.5 Certifications
    22.4 Axsome Therapeutics
    22.4.1 Financial Analysis
    22.4.2 Product Portfolio
    22.4.3 Demographic Reach and Achievements
    22.4.4 Mergers and Acquisition
    22.4.5 Certifications
    22.5 Alkermes
    22.5.1 Financial Analysis
    22.5.2 Product Portfolio
    22.5.3 Demographic Reach and Achievements
    22.5.4 Mergers and Acquisition
    22.5.5 Certifications
    22.6 Intra-Cellular Therapies
    22.6.1 Financial Analysis
    22.6.2 Product Portfolio
    22.6.3 Demographic Reach and Achievements
    22.6.4 Mergers and Acquisition
    22.6.5 Certifications
    22.7 Allergan plc
    22.7.1 Financial Analysis
    22.7.2 Product Portfolio
    22.7.3 Demographic Reach and Achievements
    22.7.4 Mergers and Acquisition
    22.7.5 Certifications
    22.8 Pfizer Inc.
    22.8.1 Financial Analysis
    22.8.2 Product Portfolio
    22.8.3 Demographic Reach and Achievements
    22.8.4 Mergers and Acquisition
    22.8.5 Certifications
    22.9 Sanofi S.A.
    22.9.1 Financial Analysis
    22.9.2 Product Portfolio
    22.9.3 Demographic Reach and Achievements
    22.9.4 Mergers and Acquisition
    22.9.5 Certifications
    22.10 Johnson & Johnson
    22.10.1 Financial Analysis
    22.10.2 Product Portfolio
    22.10.3 Demographic Reach and Achievements
    22.10.4 Mergers and Acquisition
    22.10.5 Certifications
    22.11 Merck & Co.
    22.11.1 Financial Analysis
    22.11.2 Product Portfolio
    22.11.3 Demographic Reach and Achievements
    22.11.4 Mergers and Acquisition
    22.11.5 Certifications
    22.12 Eli Lilly and Company
    22.12.1 Financial Analysis
    22.12.2 Product Portfolio
    22.12.3 Demographic Reach and Achievements
    22.12.4 Mergers and Acquisition
    22.12.5 Certifications
    22.13 Takeda Pharmaceutical Company Limited
    22.13.1 Financial Analysis
    22.13.2 Product Portfolio
    22.13.3 Demographic Reach and Achievements
    22.13.4 Mergers and Acquisition
    22.13.5 Certifications
    22.14 AstraZeneca Plc
    22.14.1 Financial Analysis
    22.14.2 Product Portfolio
    22.14.3 Demographic Reach and Achievements
    22.14.4 Mergers and Acquisition
    22.14.5 Certifications
    22.15 GSK plc
    22.15.1 Financial Analysis
    22.15.2 Product Portfolio
    22.15.3 Demographic Reach and Achievements
    22.15.4 Mergers and Acquisition
    22.15.5 Certifications
    23 Major Depressive Disorder Market - Distribution Model (Additional Insight)
    23.1 Overview
    23.2 Potential Distributors
    23.3 Key Parameters for Distribution Partner Assessment
    24 Key Opinion Leaders (KOL) Insights (Additional Insight)
    25 Company Competitiveness Analysis (Additional Insight)
    25.1 Very Small Companies
    25.2 Small Companies
    25.3 Mid-Sized Companies
    25.4 Large Companies
    25.5 Very Large Companies
    26 Payment Methods (Additional Insight)
    26.1 Government Funded
    26.2 Private Insurance
    26.3 Out-of-Pocket

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us